
NSE · general
Consolidating within technical boundary levels
Source: quantitative model
Favorable valuation relative to historical peers
Source: screener fundamentals
Healthy capital structure and solvency metrics
Source: screener fundamentals
Controlled volatility within expected market range
Source: quantitative model
Key facts from company filings. Model assessments are labelled and evidence stays available on demand.
Save this stock to your watchlist and follow changes in its daily research status.
Innovative Medicines business contributing 22% of consolidated sales
Robust renewable energy integration reaching 52.55% of the overall energy mix
Strong market leadership position as the largest pharmaceutical company in India
No risk factors identified.
Management outlook
Capex: Continued investments in research and development, manufacturing excellence, quality systems, and digital capabilities, along with the announced acquisition of Organon.
Management tone: BULLISH (AI assessment)